ClinicalTrials.gg
Active, not recruitingNCT06838000Updated Oct 6, 2025

Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents

A Phase 3 interventional study of PCV21 and 20vPCV in Pneumococcal Infections, sponsored by Sanofi Pasteur, a Sanofi Company. Active, not recruiting at 38 sites in 4 countries. Open to participants aged 7 Months to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-06.

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,268
Allocation
Randomized
Ages
7 Months to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections — 1 open to participants now, 2 under way, 2 of them phase 3. Pneumococcal 21-Valent Conjugate Vaccine · Pneumococcal Infections.

Enrollment
5th of 10
1,268 · median 1,075
Started
2025
the only one that year
Phase 3
9 of 10
1 open now
Registered
9th of 10
by date
Lead sponsor
1 of 10
Sanofi Pasteur, a Sanofi Company

Among the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 5th largest by enrollment, is the only one that started in 2025, is one of 9 in phase 3, and was the 9th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

1 of the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections is open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About Pneumococcal 21-Valent Conjugate Vaccine

Pneumococcal 21-Valent Conjugate Vaccine: first FDA approval 2024 (CAPVAXIVE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 7 Months to 17 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and immunogenicity of PCV21 versus 20vPCV ( 20-valent pneumococcal conjugate vaccine, Prevnar 20) for catch-up vaccination in infants (7 to 11 MoA-Months of age), toddlers (12 to 23 MoA), and children/adolescents (2 to 5 YoA and 6 to 17 YoA-years of age).

Read the detailed description

The duration of each participation will be approximately 9 to 11 months for each infant participant, 8 to 9 months for each toddler participant, and 6 months for each child/adolescent participant.

03

Conditions studied

  • Pneumococcal Infections

Keywords

  • Pneumococcal Vaccines
  • Pneumococcal Conjugate Vaccine
  • Healthy Participants
04

Who can participate

Ages eligible
7 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

AGE

  • Aged 7 months to 17 years on the day of inclusion

TYPE OF PARTICIPANT AND DISEASE CHARACTERISTICS

  • Participants who are healthy as determined by medical evaluation including medical history and physical examination

For infants (7 to 11 MoA) and toddlers (12 to 23 MoA) only

  • Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5 kg or born after a gestation period above 28 (> 28 weeks) through 36 weeks with a birth weight ≥ 1.5 kg, and in both cases medically stable as assessed by the investigator

SEX, /BARRIER METHOD AND PREGNANCY TESTING REQUIREMENTS For adolescents (6 to 17 YoA) only

  • A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:
  • Is of non-. To be considered of non-childbearing potential, a female must be pre-menarche or surgically sterile. OR
  • Is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to the study vaccine administration until at least 4 weeks after the study vaccine administration. A female participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 25 hours of before the first dose of study vaccine.

  • Assent form has been signed and dated by the participant (based on local regulations), and if applicable, and informed consent form has been signed and dated by the parent(s) or another legally acceptable representative (LAR) and by an independent witness, if required by local regulations

OTHER INCLUSIONS

  • Participant and parent(s) / LAR(s) are able to attend all scheduled visits and to comply with all study procedures

Exclusion criteria

Exclusion Criteria:

MEDICAL CONDITIONS

  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic therapy
  • History of microbiologically confirmed S. pneumoniae infection or disease
  • History of seizure or significant stable or progressive neurological disorders such as inflammatory nervous system diseases, encephalopathy, and cerebral palsy
  • Known systemic to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the study or to a product containing any of the same substances
  • Laboratory-confirmed thrombocytopenia, or known thrombocytopenia, as reported by the parent(s) / LAR(s), contraindicating intramuscular (IM) injection
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM injection
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
  • Moderate or severe acute illness/infection (according to investigator judgment) or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]) on the day of vaccine administration.

For infants (7 to 11 MoA) and toddlers (12 to 23 MoA) only

  • Previous vaccination against S. pneumonia

For children (2 to 5 YoA) and adolescents (6 to 17 YoA) only

  • Previous vaccination with pneumococcal polysaccharide vaccine

For adolescents (6 to 17 YoA) only

  • Alcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion

PRIOR/CONCOMITANT THERAPY

  • Receipt of any vaccine in the 4 weeks preceding the vaccine administration or planned receipt of any vaccine in the 4 weeks following the vaccine administration, except for US licensed influenza vaccination, which may be received at least 2 weeks before or 2 weeks after any study vaccination. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines, as applicable per local recommendations
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months

For children (2 to 5 YoA) and adolescents (6 to 17 YoA) only

  • Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw

PRIOR/CONCURRENT CLINICAL STUDY EXPERIENCE

  • Participation at the time of study enrollment (or in the 6 weeks preceding the first vaccine administration) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure

OTHER EXCLUSIONS For adolescents (6 to 17 YoA) only

  • Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
  • Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
1,268 participants (actual)

Study arms

  • Experimental
    Infants (7 to 11 MoA)

    Participants will receive 3 intramuscular injections of pneumococcal vaccine with an interval of: * 4 to 8 weeks (28 to 56 days) between the 1st dose and the 2nd dose * 8 to 12 weeks (56 to 84 days) between the 2nd dose and the 3rd dose AND age ≥ 12 MoA at 3rd dose

    Biological: PCV21 · Biological: 20vPCV

  • Experimental
    Toddlers (12 to 23 MoA)

    Participants will receive 2 intramuscular injections of the pneumococcal vaccine with an interval of 8 to 12 weeks (56 to 84 days) between doses

    Biological: PCV21 · Biological: 20vPCV

  • Experimental
    Children/adolescent (2 to 5 and 6 to 17 YoA)

    Participants will receive 1 intramuscular injection of the pneumococcal vaccine

    Biological: PCV21 · Biological: 20vPCV

Interventions

  • BiologicalPCV21

    Investigational pneumococcal conjugate vaccine

  • Biological20vPCV

    20-valent pneumococcal conjugate vaccine

06

What researchers measure

Primary outcomes

  1. Number of participants reporting immediate adverse events (AEs)

    Unsolicited (spontaneously reported) systemic AEs after each and any injection of a pneumococcal vaccine

    Time frame: Within 30 minutes post-vaccination

  2. Number of participants reporting solicited injection site and solicited systemic reactions

    Time frame: Up to Day 7 post-vaccination

  3. Number of participants reporting unsolicited (spontaneously reported) injection site reactions and unsolicited systemic AEs after each and any injection of a pneumococcal vaccine

    Time frame: Within 30 days after vaccination

  4. Number of participants reporting serious adverse events (SAEs) and adverse events of special interest (AESIs)

    SAEs and AESIs are collected throughout the study period

    Time frame: From day 0 to day 517

  5. Number of Infants (7-11 months of age [MoA]) and toddlers (12-23 MoA): with serotype-specific IgG concentrations for all serotypes included in PCV21

    Ab (antibody) concentrations for each pneumococcal serotype are measured.

    Time frame: On day 30 after last vaccination

  6. Number of Children (2-5 years of age [YoA]):with serotype specific OPA titers for all serotypes included in PCV21

    Serotype specific OPA titers for each pneumococcal serotype are determined.

    Time frame: On day 30

  7. Number of Children (2-5 years of age [YoA]):with serotype specific IgG concentrations for all serotypes included in PCV21

    Ab concentrations for each pneumococcal serotype are measured.

    Time frame: On day 30

  8. Number of Children/adolescents (6-17 YoA):with serotype specific OPA titers for all serotypes included in PCV21

    Serotype specific OPA titers for each pneumococcal serotype are determined.

    Time frame: On day 30

Secondary outcomes

  1. Number of Children/adolescents (≥ 2 YoA) with serotype specific OPA titers for all serotypes included in PCV 21

    Serotype specific OPA titers for each pneumococcal serotype are determined.

    Time frame: On day 30

  2. Number of Children/adolescents (≥ 2 YoA): with serotype specific IgG concentrations for all serotypes included in PCV21

    Ab concentrations for each pneumococcal serotype are measured.

    Time frame: On day 30

  3. Number of participants (all age groups) with serotype specific IgG concentration ≥ 0.35 μg/mL for all serotypes included in PCV21

    Ab concentrations for each pneumococcal serotype are measured.

    Time frame: On day 30 after last vaccination

  4. Number of infants (7-11 MoA) and toddlers(12-23 MoA):with serotype specific OPA titers for all serotypes included in PCV21

    Serotype specific OPA titers for each pneumococcal serotype are determined.

    Time frame: On day 30 after last vaccination

  5. Percentage of infants (7-11 MoA) and toddlers(12-23 MoA): with serotype specific OPA titers ≥ LLOQ for all serotypes included in PCV21

    Serotype specific OPA titers for each pneumococcal serotype included in the PCV21 formulations are determined. The following threshold values will be considered: ≥ lower limit of quantitation (LLOQ)

    Time frame: On day 30 after last vaccination

  6. Number of Children/adolescents (6-17 YoA):with serotype specific IgG concentrations for all serotypes included in PCV21

    Ab concentrations for each pneumococcal serotype are measured.

    Time frame: On day 30

07

Study locations

38 sites
  • Site # 8400008
    Paramount, California 90723, United States
  • Site # 8400024
    Doral, Florida 33166, United States
  • Site # 8400007
    Hialeah, Florida 33012, United States
  • Site # 8400014
    Melbourne, Florida 32934, United States
  • Site # 8400009
    Miami, Florida 33166, United States
  • Site # 8400016
    Miami, Florida 33166, United States
  • Site # 8400021
    Fayetteville, Georgia 30214, United States
  • Site # 8400004
    Union City, Georgia 30291, United States
  • Site # 8400003
    Sioux City, Iowa 51106, United States
  • Site # 8400023
    Erlanger, Kentucky 41018, United States
  • Site # 8400018
    Biloxi, Mississippi 39531, United States
  • Site # 8400012
    Ridgeland, Mississippi 39531, United States
  • Site # 8400002
    Omaha, Nebraska 68114, United States
  • Site #8400010
    Binghamton, New York 13905, United States
  • Site # 8400025
    Rochester, New York 14642, United States
  • Site # 8400001
    Houston, Texas 77065, United States
  • Site # 8400017
    Stephenville, Texas 76401, United States
  • Site # 2330006
    Tallinn, Harju 10117, Estonia
  • Site # 2330007
    Tallinn, Harju 13619, Estonia
  • Site # 2330002
    Tallinn, Harju EE-10617, Estonia
  • Site # 2330003
    Tallinn, Harju EE-10617, Estonia
  • Site # 2330001
    Paide, Järvamaa 72713, Estonia
  • Site # 2330005
    Tartu, Tartu 50106, Estonia
  • Site # 2330004
    Tartu, 50708, Estonia
  • Site # 6160009
    Lodz, Lodskie 91-341, Poland
  • Site # 6160007
    Warsaw, Masovian Voivodeship 03-291, Poland
  • Site # 6160003
    Częstochowa, Silesian Voivodeship 42-200, Poland
  • Site # 6160002
    Bydgoszcz, 85-048, Poland
  • Site # 6160004
    Bydgoszcz, 85-796, Poland
  • Site # 6160006
    Kłodzko, 57-300, Poland
  • Site # 6160001
    Torun, 87-100, Poland
  • Site # 7640002
    Hat Yai, Changwat Songkhla 90112, Thailand
  • Site # 7640003
    Mueang Nonthaburi, Chiang Mai 50200, Thailand
  • Site # 7640008
    Bangkok, 10270, Thailand
  • Site # 7640006
    Bangkok, 10400, Thailand
  • Site # 7640007
    Bangkok, 10400, Thailand
  • Site # 7640004
    Chiang Mai, 50200, Thailand
  • Site # 7640001
    Pathum Thani, Thailand
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's planned 21 months is above that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2024
First posted
Feb 20, 2025
StartActual
Feb 28, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Oct 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06838000
Responsible party
Sponsor
First posted
Feb 20, 2025
Start date
Feb 28, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Oct 6, 2025

Study contacts

Clinical Sciences & Operations Study Director
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 21-Valent Conjugate Vaccine

Start the discussion